1. To ask the First Minister what engagements he has planned for the rest of the day. (S4F-01050)
Official Report · Chamber
Engagements
First Minister’s Question Time
Speakers
Choose an MSP to read only their contributions- Johann Lamont Lab 6
- Alex Salmond SNP 6
- Tricia Marwick 3
The record
15 contributions1. To ask the First Minister what engagements he has planned for the rest of the day. (S4F-01050)
Later today I will speak with Steve Frisch, regional president of the global electronics manufacturer Plexus, which I am delighted to announce is creating 130 jobs as part of a £9 million investment in Bathgate, West Lothian. After the disappointment of Vion deciding to close its operations, today’s announcement will be very welcome news for the people of West Lothian and is an early result for the West Lothian recovery strategy.
It is appropriate to pay tribute to John Park, who I understand is shortly to stand down as a member of the Scottish Parliament. He has made a considerable contribution to our proceedings over the years.
In light of everything, we should also congratulate Celtic on qualifying for the European championship. I think that Neil Lennon is on his way to becoming a legend.
It is appropriate to pay tribute to John Park, who I understand is shortly to stand down as a member of the Scottish Parliament. He has made a considerable contribution to our proceedings over the years.
In light of everything, we should also congratulate Celtic on qualifying for the European championship. I think that Neil Lennon is on his way to becoming a legend.
The only word that I would dispute there is “becoming”—maybe we can discuss that later.
I welcome the First Minister’s comments about jobs and about John Park’s decision to stand down. I am sure that we all wish John Park well. Labour members will miss him very much, but we know that in his new job he will continue to engage with the struggle, the battles and the values in which he believes as well as he has done in the past.
This week, doctors called for honesty from politicians on cancer treatment. Alex Neil has announced a review of access to new medicines, which I welcome. Of course, under Nicola Sturgeon, Scotland went from being the top nation in the United Kingdom for using innovative drugs to being the worst. Will the First Minister explain why Scots do not get access to the latest cancer drugs on the national health service?
I welcome the First Minister’s comments about jobs and about John Park’s decision to stand down. I am sure that we all wish John Park well. Labour members will miss him very much, but we know that in his new job he will continue to engage with the struggle, the battles and the values in which he believes as well as he has done in the past.
This week, doctors called for honesty from politicians on cancer treatment. Alex Neil has announced a review of access to new medicines, which I welcome. Of course, under Nicola Sturgeon, Scotland went from being the top nation in the United Kingdom for using innovative drugs to being the worst. Will the First Minister explain why Scots do not get access to the latest cancer drugs on the national health service?
The process by which the Scottish Medicines Consortium looks at such matters is robust and has been supported by all parties, and it would be very unwise to change it.
The recent controversy concerns the introduction in the English health service of a special cancer drugs fund. That introduction has been opposed in Scotland, by not just the Scottish National Party but the Labour Party and the Liberal Democrats, and it has been opposed by the Welsh Assembly Government, basically because the fund does not fulfil many of the things that are claimed for it. In particular, it introduces in England a postcode lottery. There is criticism from the range of charities that submitted evidence to the Parliament, which cannot see the reason for having a specific cancer drugs fund when other, equally serious, conditions do not have such a fund.
We should be confident that the SMC process in Scotland is a robust one and we should continue our all-party support for the integrity of the process.
The recent controversy concerns the introduction in the English health service of a special cancer drugs fund. That introduction has been opposed in Scotland, by not just the Scottish National Party but the Labour Party and the Liberal Democrats, and it has been opposed by the Welsh Assembly Government, basically because the fund does not fulfil many of the things that are claimed for it. In particular, it introduces in England a postcode lottery. There is criticism from the range of charities that submitted evidence to the Parliament, which cannot see the reason for having a specific cancer drugs fund when other, equally serious, conditions do not have such a fund.
We should be confident that the SMC process in Scotland is a robust one and we should continue our all-party support for the integrity of the process.
I did not ask the First Minister for a critique of what is happening elsewhere; I asked him about his responsibility. He said that a cancer drugs fund might create a postcode lottery. Is he not aware that there is currently a postcode lottery in Scotland?
There is no test of cost-benefit for my free hay fever tablets, but such a test is applied to cancer drugs. Let us look at the reality. This morning, we spoke to Iain Morrison. He is 56 and suffers from bowel cancer. He has to pay £1,700 a fortnight for the drugs that he hopes will prolong his life. What is astonishing is that part of that cost is an administration charge from the NHS, so that he can get the drugs that the NHS will not give him for free.
As patients suffer, doctors despair. Dr Tim Crook told the Parliament this week:
“As an Englishman looking after patients in Scotland, I think that there is an inequality that, to my mind as a simple doctor, is unacceptable, in that I cannot offer my Scottish patients the same medication with which I could treat my English patients. As a human being and a doctor, I do not see how that can be right.”—[Official Report, Health and Sport Committee, 4 December 2012; c 2988.]
Does the First Minister think that that is right?
There is no test of cost-benefit for my free hay fever tablets, but such a test is applied to cancer drugs. Let us look at the reality. This morning, we spoke to Iain Morrison. He is 56 and suffers from bowel cancer. He has to pay £1,700 a fortnight for the drugs that he hopes will prolong his life. What is astonishing is that part of that cost is an administration charge from the NHS, so that he can get the drugs that the NHS will not give him for free.
As patients suffer, doctors despair. Dr Tim Crook told the Parliament this week:
“As an Englishman looking after patients in Scotland, I think that there is an inequality that, to my mind as a simple doctor, is unacceptable, in that I cannot offer my Scottish patients the same medication with which I could treat my English patients. As a human being and a doctor, I do not see how that can be right.”—[Official Report, Health and Sport Committee, 4 December 2012; c 2988.]
Does the First Minister think that that is right?
That refers specifically—I saw the quote and, indeed, the evidence to the committee—to the introduction in England of the special cancer drugs fund. The committee also heard from the Scottish cancer research network lead, Dr David Dunlop, who referred to
“the cancer drugs fund, which clinicians south of the border say is far from perfect. In fact, that fund brings more postcode prescribing than existed previously, because each of the different strategic health authorities has a different shopping list that is influenced by its clinicians.”—[Official Report, Health and Sport Committee, 4 December 2012; c 2986.]
Incidentally, that position has previously been supported by the Labour Party in this chamber.
We should always look for ways to improve the position and we should always look for ways in which the Scottish Medicines Consortium can be even better in progressing its work, but I point out that that is exactly why the health secretary Alex Neil has set up the investigation by Professor Routledge, who is looking specifically at how we can improve the situation in Scotland.
In this extraordinarily difficult area, I do not think that it is particularly helpful to give quotations that refer to the existence of a special cancer drugs fund, which we have thus far decided is not appropriate in Scotland for the reasons that I have given. We should also hear the evidence from the cancer charities and others who support the work of the SMC and who point out the advantages of the SMC process.
This is a matter that we must consider, as a Government and as a Parliament, with the utmost care and sensitivity, because it obviously touches on life-limiting conditions and people in conditions of great extremity. I think that Johann Lamont should accept that, thus far at least, the SMC process has enjoyed cross-party, robust support in Scotland, and I think that we should be very careful about departing from that established process of integrity.
“the cancer drugs fund, which clinicians south of the border say is far from perfect. In fact, that fund brings more postcode prescribing than existed previously, because each of the different strategic health authorities has a different shopping list that is influenced by its clinicians.”—[Official Report, Health and Sport Committee, 4 December 2012; c 2986.]
Incidentally, that position has previously been supported by the Labour Party in this chamber.
We should always look for ways to improve the position and we should always look for ways in which the Scottish Medicines Consortium can be even better in progressing its work, but I point out that that is exactly why the health secretary Alex Neil has set up the investigation by Professor Routledge, who is looking specifically at how we can improve the situation in Scotland.
In this extraordinarily difficult area, I do not think that it is particularly helpful to give quotations that refer to the existence of a special cancer drugs fund, which we have thus far decided is not appropriate in Scotland for the reasons that I have given. We should also hear the evidence from the cancer charities and others who support the work of the SMC and who point out the advantages of the SMC process.
This is a matter that we must consider, as a Government and as a Parliament, with the utmost care and sensitivity, because it obviously touches on life-limiting conditions and people in conditions of great extremity. I think that Johann Lamont should accept that, thus far at least, the SMC process has enjoyed cross-party, robust support in Scotland, and I think that we should be very careful about departing from that established process of integrity.
The First Minister ought to stop accusing me of doing things that I am not doing, and he ought to stop arguing about something that I am not arguing for. I do not need anyone to tell me how serious an issue this is—nobody in here does. What I am saying to him is that there is a postcode lottery in Scotland, and I have described a particular case. This is a very serious issue, but the First Minister’s response seems to be that what we have is very good. I am not promoting a particular model to solve this; I am asking the First Minister to confront the fact that there is a major problem.
The issue affects not just those people whom I have already described. The inequality is not just between Scotland and England; there is an even greater inequality within Scotland. Dr Noelle O’Rourke of the Beatson cancer centre told the Parliament’s Health and Sport Committee this week that middle-class, articulate patients are more likely to get the cancer drugs that they need than vulnerable patients from deprived backgrounds. She said that patients in less need receive treatments that are denied others in greater clinical need because they are more articulate. Dr O’Rourke described that as “inequitable”. Does the First Minister agree?
The issue affects not just those people whom I have already described. The inequality is not just between Scotland and England; there is an even greater inequality within Scotland. Dr Noelle O’Rourke of the Beatson cancer centre told the Parliament’s Health and Sport Committee this week that middle-class, articulate patients are more likely to get the cancer drugs that they need than vulnerable patients from deprived backgrounds. She said that patients in less need receive treatments that are denied others in greater clinical need because they are more articulate. Dr O’Rourke described that as “inequitable”. Does the First Minister agree?
The reason that I made those points to Johann Lamont is that the quote that she gave was an illustration of the impact of the introduction of the special cancer drugs fund in England. I am looking at the evidence and the argument is that there are drugs available in England because of the special cancer drugs fund, but those are not available in every part of England. The committee has heard evidence—and I suspect will hear more evidence—of the drawbacks of that particular system.
The reason that I point to the robustness of the SMC process is not to argue that the position that we have in Scotland is perfect. If we thought that the position was perfect, we would not have set up the Routledge review in order to see how we can improve the situation. However, in Scotland the time that the SMC takes to produce guidance, following authorisation for drugs, is just over seven months; the equivalent time in England is 21 months. There is much evidence from the charities and people affected on why they appreciate the speed with which the SMC goes about its work.
There are important improvements that we have made to the process of individual patient treatment requests. The purpose, among other things, of Professor Routledge’s review is to see how we can improve that further.
Johann Lamont says that she is not proposing a particular solution. It would be helpful as we contribute to the debate—I hope that this is what the Health and Sport Committee will do—if people would contribute positive suggestions as to how we can improve the situation. However, that should be done with a recognition that what we are dealing with, whether it is in Scotland, England, Wales or wherever, is an extremely serious issue; that we are doing our best to deal with it; that the SMC’s process is robust; and that the Routledge review is there to make further improvements on behalf of the people of Scotland.
The reason that I point to the robustness of the SMC process is not to argue that the position that we have in Scotland is perfect. If we thought that the position was perfect, we would not have set up the Routledge review in order to see how we can improve the situation. However, in Scotland the time that the SMC takes to produce guidance, following authorisation for drugs, is just over seven months; the equivalent time in England is 21 months. There is much evidence from the charities and people affected on why they appreciate the speed with which the SMC goes about its work.
There are important improvements that we have made to the process of individual patient treatment requests. The purpose, among other things, of Professor Routledge’s review is to see how we can improve that further.
Johann Lamont says that she is not proposing a particular solution. It would be helpful as we contribute to the debate—I hope that this is what the Health and Sport Committee will do—if people would contribute positive suggestions as to how we can improve the situation. However, that should be done with a recognition that what we are dealing with, whether it is in Scotland, England, Wales or wherever, is an extremely serious issue; that we are doing our best to deal with it; that the SMC’s process is robust; and that the Routledge review is there to make further improvements on behalf of the people of Scotland.
Of course, the doctor referred to was talking not about the SMC but about the individual patient treatment request, into which a review was conducted.
My point is that the review needs to be broader than the remit that has been given to it because of the huge challenges.
The First Minister says that we should have an open and honest debate about this. When I questioned his priorities in health spending, I was accused of wanting to tax the sick and that debate was quickly closed down. This is all part of the same serious process because it is not just about patients getting the latest drugs. The NHS in Scotland spends only just over half the European average on cancer drugs. Cancer specialists do not want to work here. Dr Richard Casasola told this Parliament—[Interruption.]
My point is that the review needs to be broader than the remit that has been given to it because of the huge challenges.
The First Minister says that we should have an open and honest debate about this. When I questioned his priorities in health spending, I was accused of wanting to tax the sick and that debate was quickly closed down. This is all part of the same serious process because it is not just about patients getting the latest drugs. The NHS in Scotland spends only just over half the European average on cancer drugs. Cancer specialists do not want to work here. Dr Richard Casasola told this Parliament—[Interruption.]
Tricia Marwick
The Presiding Officer · Mid Fife and Glenrothes
link
Order.
Dr Richard Casasola told this Parliament this week that every Scottish cancer centre is at least one specialist short and that the most gifted doctors do not want to work here because they cannot prescribe the latest drugs.
We are not able to be at the cutting edge because of the choices that the First Minister has made about the way in which drugs are accessed. Will the First Minister please be honest with cancer patients and specialists and confront the reality that this is the result of choices that he has made and it is about his priorities for spending in the NHS? [Interruption.]
We are not able to be at the cutting edge because of the choices that the First Minister has made about the way in which drugs are accessed. Will the First Minister please be honest with cancer patients and specialists and confront the reality that this is the result of choices that he has made and it is about his priorities for spending in the NHS? [Interruption.]
Tricia Marwick
The Presiding Officer · Mid Fife and Glenrothes
link
Order.
Johann Lamont should accept the substantial efforts and spending on cancer research in Scotland and cancer centres, the substantial increase in the successful outcomes for cancer that we are seeing, and the abidance—for the first time, I think—of the target to have 95 per cent of cancer patients seen in a specified period. The figure when Labour was in office was 85 per cent. Those are all substantial improvements in the service that we are able to offer.
When I argue that the SMC has a robust process that we should reflect on, be proud of and be careful about overturning, I am not just saying that as the First Minister. Myeloma UK, for example, says:
“The modifiers that the SMC use in their decision-making are applied more pragmatically than the comparable but not identical ... criteria used by the National Institute for Health and Clinical Excellence (NICE).”
It says that it prefers the SMC approach to the approach south of the border. That the SMC process is robust has substantial support from many people.
There is much evidence that the individual patient treatment request process, which applies to drugs that have not been authorised by the SMC, has factors in it that could be improved, and the health secretary set up Professor Routledge’s review to see whether we could improve the situation further.
Johann Lamont should be careful about suggesting that cancer treatment in Scotland is not improving, because it is. She should not say that there is not a commitment to cancer research, because there most certainly is. [Interruption.]
When I argue that the SMC has a robust process that we should reflect on, be proud of and be careful about overturning, I am not just saying that as the First Minister. Myeloma UK, for example, says:
“The modifiers that the SMC use in their decision-making are applied more pragmatically than the comparable but not identical ... criteria used by the National Institute for Health and Clinical Excellence (NICE).”
It says that it prefers the SMC approach to the approach south of the border. That the SMC process is robust has substantial support from many people.
There is much evidence that the individual patient treatment request process, which applies to drugs that have not been authorised by the SMC, has factors in it that could be improved, and the health secretary set up Professor Routledge’s review to see whether we could improve the situation further.
Johann Lamont should be careful about suggesting that cancer treatment in Scotland is not improving, because it is. She should not say that there is not a commitment to cancer research, because there most certainly is. [Interruption.]
Tricia Marwick
The Presiding Officer · Mid Fife and Glenrothes
link
Order.
Well, £6 million is being spent on 24 cancer research projects by the chief scientist’s office.
Johann Lamont should also accept that we are dealing with hugely difficult circumstances around how to successfully approve and make available to the people of Scotland new, experimental drugs that become available; how to find a safe process for authorising them; and how to find the best possible way of making them available to the community of Scotland.
Every single person in the chamber is committed to better outcomes for cancer patients in Scotland. Let us go forward to find that better solution, supporting the Routledge review, in an atmosphere that accepts that in essence this cannot be seen as a party-political matter but as a matter of trying to improve the health and welfare of the people of Scotland.
Johann Lamont should also accept that we are dealing with hugely difficult circumstances around how to successfully approve and make available to the people of Scotland new, experimental drugs that become available; how to find a safe process for authorising them; and how to find the best possible way of making them available to the community of Scotland.
Every single person in the chamber is committed to better outcomes for cancer patients in Scotland. Let us go forward to find that better solution, supporting the Routledge review, in an atmosphere that accepts that in essence this cannot be seen as a party-political matter but as a matter of trying to improve the health and welfare of the people of Scotland.
Motions, questions and votes
Linked from this item of the Official ReportIn this meeting
Everything on 6 Dec 2012 →- Food and Drink (Protected Geographical Indication Status) Questions · 7
- Sewage Treatment Plants Questions · 8
- Crime (Lanarkshire) Questions · 4
- Norovirus Questions · 5
- Police Officers (Lothian and Borders Police) Questions · 6
- Waiting Times (Accident and Emergency) Questions · 4
- Pharmacies (Applications and Appeals) Questions · 7
- Engagements First Minister’s Questions · 15
- Prime Minister (Meetings) First Minister’s Questions · 13
- Autumn Budget Statement First Minister’s Questions · 4
- Transport Network (Winter Preparations) First Minister’s Questions · 7
- Mental Health (Supreme Court Ruling) First Minister’s Questions · 4
- Waiting Times (Cancer Patients) First Minister’s Questions · 6
- Bobath Scotland Members’ business · 10
- Rail Statement · 32
- Careers Services Debate · 104
- Points of Order Procedure · 8
- Decision Time Decision time · 10
The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.